GlassScriptPhysician profile
Matthew G Meschke
NPI 1164442844
$7,577.92
in general payments reported to CMS, 2019-2025
44 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $676 · 2021: $1,223 · 2022: $956 · 2023: $1,114 · 2024: $1,423 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.49 | 2020-2025 | |
| Amgen INC. | $823.48 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $717.83 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $643.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $621.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $525.33 | 2020-2025 | |
| Glaxosmithkline, LLC. | $352.68 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Astellas Pharma US INC | $246.28 | 2019-2025 | Veozah |
| Abbott Laboratories | $238.94 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $212.53 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.64 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $167.10 | 2019-2022 | |
| Antares Pharma, INC. | $163.79 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.54 | 2019-2024 | Jardiance |
| Allergan, INC. | $160.49 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meschke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.